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Abstract
Background:  Retrovirus-induced tumors develop in a broad range of frequencies and after
extremely variable periods of time, from only a few days to several decades, depending mainly on
virus type. For hitherto unexplained reasons, deltaretroviruses cause hematological malignancies
only in a minority of naturally infected organisms and after a very prolonged period of clinical
latency.
Results: Here we demonstrate that the development of malignancies in sheep experimentally
infected with the deltaretrovirus bovine leukemia virus (BLV) depends only on the level of BLV
replication. Animals were experimentally infected with leukemogenic or attenuated, but infectious,
BLV molecular clones and monitored prospectively through 8 months for viral replication. As early
as 2 weeks after infection and subsequently at any time during follow-up, leukemogenic viruses
produced significantly higher absolute levels of reverse transcription (RT), clonal expansion of
infected cells, and circulating proviruses with RT- and somatic-dependent mutations than
attenuated viruses. These differences were only quantitative, and both kinds of viruses triggered
parallel temporal fluctuations of host lymphoid cells, viral loads, infected cell clonality and
proliferation.
Conclusion: Deltaretrovirus-associated leukemogenesis in sheep appears to be a two-hit process
over time depending on the amounts of first horizontally and then vertically expanded viruses.
Background
Oncogenic retroviruses are known to cause cancers by the
acquisition and expression of host-derived oncogenes, by
the insertional activation of host cell oncogenes, and the
expression of viral proteins such as those encoded by the
tax  or the HBZ  genes of human T-cell leukemia virus
(HTLV) [1], or by the envelope gene of the Jaagsiekte
sheep retrovirus (JSRV) [2,3]. Tumors develop in a very
broad range of frequencies and after extremely variable
periods of time, depending mainly on the virus type, but
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also on the viral strain, the host genetic background, exog-
enous cofactors, and combinations thereof. For example,
JSRV can induce lung adenocarcinoma in newborn lambs
in as little as 10 days following experimental inoculation
[4]; while after infection with acute transforming retrovi-
ruses such as the Rous sarcoma virus (RSV) infection,
tumors develop after a few weeks in almost all infected
chickens [5]. In strong contrast, less than 5% of deltaret-
rovirus-infected organisms develop leukemia after very
prolonged periods of latency. In fact, leukemogenic del-
taretroviruses are the least oncogenic retroviruses in term
of disease penetrance in their naturally infected host. In
humans, adult T-cell leukemia/lymphoma (ATLL) occurs
only in about 1–3% of individuals infected with HTLV-
1[6]. In monkeys, the incidence of STLV-associated malig-
nancies seems along the same order [7], while in infected
cows BLV triggers leukemia in about 5% of the animals
[8]. In addition to a low incidence, deltaretrovirus-associ-
ated malignancies commonly develop after a prolonged
period of latency that encompasses about two thirds of
the predicted lifespan of the respective hosts [6-8]. This
very low leukemogenic effect in vivo is in sharp contrast
with the extremely high level of oncogenicity that charac-
terizes these viruses ex vivo. They encode proteins such as
Tax or HBZ which can transform cells by interfering with
numerous cellular pathways involved in tumor promo-
tion and maintenance [1].
For HTLV-1, infection occurring early in the life of the host
is crucial in the development of ATLL[6]. Furthermore, the
disease has been found to occur more frequently and
more rapidly in individuals suffering from strongyloidia-
sis or infectious dermatitis, two clinical conditions charac-
terized at the asymptomatic phase of HTLV-1 infection, by
extremely high circulating proviral loads [9-11]. Similarly,
ATLL cases retrospectively analyzed at the asymptomatic
phase of infection have been found to display higher cir-
culating proviral loads than disease-free carriers from the
same geographic area [12]. In animal models, such as
squirrel monkeys infected with HTLV-1 or sheep infected
with BLV, we and others previously observed that deltaret-
roviral leukemogenesis regularly includes a progressive
increase of proviral load related to the proliferation of pre-
leukemic clones [13,14].
Although they are retrospective or uncontrolled, these
data led us to test the hypothesis of a link between intense
deltaretroviral replication and subsequent tumor develop-
ment. It is possible to genetically modulate the oncogenic-
ity of BLV molecular clones without altering their ability
to experimentally infect sheep [8,15,16]. We reasoned
that the prospective comparison of early BLV replication
in animals infected with leukemogenic versus attenuated
infectious molecular clones would be appropriate for
investigating the implication of qualitative and/or quanti-
tative alterations of deltaretrovirus replication in the sub-
sequent development of malignancies.
Results
Twelve sheep were infected by direct inoculation of a
cloned BLV provirus, as previously described [14]. Six ani-
mals were infected with the leukemogenic BLV infectious
molecular clones pBLV344, pBLVTax106+293 and
pBLVA60V (2 animals per clone, see methods). These
molecularly cloned viruses are characterized as leuke-
mogenic strains because they induce leukemias in almost
all infected sheep after a relatively short clinical latency
period ranging from 1 to 4 years. Six additional sheep
were infected with cloned viruses pBLVCRX3, pBLVIG4
and pBLVCRE3X [15] (2 animals per clone, see methods).
While mutated in different proviral sequences including
R3, G4 or LTR, these BLV molecular clones remained
infectious but have lost the ability to induce leukemia in
sheep after a mean of 66 months follow-up (26 – 84
months). Two additional sheep inoculated with a BLV-
negative solution served as controls. All 12 experimentally
infected sheep seroconverted and developed persistent
infection. The seroconversion occurred 24, 28, 42, 58, 65
and 79 (mean ± SD, 49.3 ± 18) days post-infection for the
leukemogenic BLV infected sheep 4546, 4536, 4544,
1048, 4545 and 4535; and 21, 28, 31, 35, 49 and 65
(mean ± SD, 38.2 ± 12.5) days post-infection for the atten-
uated BLV infected sheep 4538, 4543, 4537, 4541, 4542
and 4539 respectively. This difference was not statistically
significant (p > 0.05, Mann-Whitney test) indicating that
attenuated BLV molecular clones did not induce delayed
seroconversion. For each animal, blood samples were pro-
spectively collected by jugular venipuncture and prepared
for analyses on the date of seroconversion, 3 days before,
and 3, 50, and 240 days after experimental infection. All
animals infected with leukemogenic viruses were investi-
gated prior to tumor onset. As previously described [17],
experimental primary BLV infection resulted in transient
hyperleukocytosis and B lymphocytosis without signifi-
cant differences between animals infected with leuke-
mogenic versus attenuated viruses. This indicates that
initial infection with the two different groups of viruses
resulted in similar primary symptoms. The 2 groups of
infected sheep were compared for BLV replication using
the experimental strategy illustrated in Figure 1.
We first evaluated the effect of oncogenic versus attenu-
ated viruses on the overall amount of proviral sequences
over time. Quantitative real-time PCR amplification of the
conserved BLV tax gene was carried out in 60 samples iso-
lated from the 12 experimentally infected sheep during
the first 8 months of the infection (Figure 2A). The mean
BLV copy numbers per mcg of DNA in the 30 samples
derived from the 6 animals infected with leukemogenic
infectious molecular clones was ~6 times higher than thatRetrovirology 2009, 6:30 http://www.retrovirology.com/content/6/1/30
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of animals experimentally infected with attenuated strains
(8893 vs 1483, p < 10-4, Mann-Whitney test) (Figure 3A).
Figure 2A shows an increase in the mean proviral load in
leukemogenic BLV carriers at 240 days postinfection.
However this effect was related to an extreme proviral
load, up to 54000 proviral copies per mcg of DNA, carried
by the sheep 4535 (not shown). Except for this time-
point, the fluctuations in the circulating proviral loads of
leukemogenic viruses paralleled those of attenuated
strains. Altogether these data indicated that a simple
quantitative effect distinguishes the circulating proviral
loads of leukemogenic from those of attenuated viruses
without modifying their qualitative distribution.
As with other deltaretroviruses, BLV possesses two routes
of replication that include reverse-transcription and the
clonal expansion of its host cells [14]. In a recent report,
we have shown that both co-exist during primary infec-
tion while clonal expansion seems to predominate during
the chronic phase of the infection [18]. As leukemogenic
molecular clones triggered elevated circulating proviral
loads in vivo, we next investigated whether these differ-
ences in circulating proviral loads depended on the level
of RT-based, horizontal BLV replication or rather on the
level of clonal expansion of BLV positive cells. As both
processes co-exist during the early phase of the infection
[18,19], we focused our analyses on the first months fol-
lowing experimental infection. Inverse PCR amplification
of BLV 3' integration sites was carried out as already
described [14,18] for estimating the number of BLV inte-
gration events (i.e. the number of entire horizontal RT-
dependent transmission events that resulted in proviral
integration and clonal expansion of infected cells during
primary infection). The number of BLV integration events
was measured over time in each animal at the same times
that the proviral loads were quantified (Figures 2B and 4).
After quadruplicate IPCR, the mean number of integra-
tion events detected in the 30 samples deriving from the 6
animals infected with leukemogenic infectious molecular
clones varied from 9 to 126; those data from animals
infected with attenuated infectious strains varied from 6
to 96 (Figure 3B). The mean ± standard error of mean
(s.e.m.) and the median of detected integration events
were 76 ± 6 and 75 for samples derived from animals
infected with leukemogenic clones, and 39 ± 5 and 35 for
samples derived from animals infected with attenuated
clones. As shown in figure 3, the difference between the
two groups of samples was statistically significant (p < 10-
Experimental strategy Figure 1
Experimental strategy. Twelve sheep were infected by direct inoculation of a cloned BLV provirus. Six animals (top) were 
infected with the leukemogenic BLV infectious molecular clones pBLV344, pBLVTax106+293 and pBLVA60V (2 animals per 
clone). These molecularly cloned viruses induce leukemias in almost all infected animals. Six additional sheep (bottom) were 
infected with the infectious, but attenuated, cloned viruses pBLVCRX3, pBLVIG4 and pBLVCRE3X [15] (2 animals per clone). 
All 12 experimentally infected sheep seroconverted and developed persistent infection. For each animal, blood samples were 
prospectively collected by jugular venipuncture and prepared for analyses at the date of seroconversion, 3 days before, 3 and 
50 days after, and 240 days after experimental infection. All animals infected with leukemogenic viruses were investigated prior 
to tumor onset. The 2 groups of infected sheep were compared for BLV replication by using quantitative analyses of circulating 
proviral loads, reverse-transcription (RT) events, RT-dependent genetic variability, clonal expansion, and somatic mutations.
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Temporal fluctuations of leukemogenic versus attenuated virus replication in vivo after experimental infection Figure 2
Temporal fluctuations of leukemogenic versus attenuated virus replication in vivo after experimental infection. 
Early Bovine Leukemia Virus replication was compared over time between sheep infected with attenuated (open circles) versus 
leukemogenic (black circles) infectious molecular clones. S-3: 3 days before serconversion, S: seroconversion, S+3: 3 days after 
seroconversion, S+50: 50 days after seroconversion, i+240: 240 days post-incoculation. Comparisons were made for circulat-
ing proviral loads (A), overall measured RT events (B), abundant clones (C), less extensively expanded clones (clones < 62.5 
copies per 1 mcg of DNA) (D), somatic (black histograms) and RT-dependent (grey histograms) proviral mutations; white his-
tograms represent unmutated clones (E). Error bars are ± standard error of mean.
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4, Mann-Whitney test). In contrast, temporal fluctuations
of BLV integration events were found to be parallel for
leukemogenic and attenuated infectious molecular clones
(Figure 2B). These data indicated that BLV leukemogenic-
ity depends on the level of RT-dependent BLV replication
in vivo.
Next, we tested whether the leukemogenicity of molecu-
larly cloned viruses impacted the level of cell-associated
BLV replication. To this end we measured by semiquanti-
tative quadruplicate IPCR the degree of clonal expansion
of infected cells over time in each animal (Figures 2C, 2D
and 4). The mean number of abundant clones (detected ≥
2/4 IPCR experiments corresponding to ≥ 62.5 copies per
1 μg of DNA [14]) in the 30 samples derived from the 6
animals infected with leukemogenic infectious molecular
clones varied from 0 in 2 samples to 34; in animals
infected with attenuated infectious strains, the numbers
varied from 0 in 16 samples to 10 (Figure 2C). The mean
± standard error of mean (s.e.m.) and median of the
number of circulating abundant BLV-positive clones were
6.5 ± 1.3 and 4.5 for samples derived from animals
infected with leukemogenic clones, and 1.2 ± 0.4 and 0
for samples derived from animals infected with leuke-
mogenic clones. As shown in figure 3C, the difference
between the two groups was statistically significant (p <
Leukemogenic molecular clones trigger higher levels of early BLV replication than attenuated infectious molecular clones in vivo Figure 3
Leukemogenic molecular clones trigger higher levels of early BLV replication than attenuated infectious 
molecular clones in vivo. Time-point data were pooled and compared between leukemogenic and attenuated infections. A: 
proviral copy (VCN) number per mcg of DNA; B: overall number of circulating infected cellular clones; C: Numbers of abun-
dant clones were defined as those giving two or more signals after semiquantitative quadruplicate IPCR, i.e. those correspond-
ing to ≥ 62.5 copies in 1 mcg of circulating DNA [14] ; D: infected cellular clones with < 62,5 copies per mcg of DNA. The 
boxes represent the difference between the 75th percentile and the 25th percentile of the variables (i.e., the interquartile 
range). Within the inset box, the median is represented by a thick horizontal line. Lines from the ends of the box extend as far 
as the most extreme values not considered outliers. Points more than 1.5 times the interquartile range from the ends of the 
box are labeled as outliers ([open circle]) or as extreme values ([low asterisk]).Retrovirology 2009, 6:30 http://www.retrovirology.com/content/6/1/30
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Clonal distribution of BLV positive cells in sheep infected by leukemogenic versus attenuated viruses Figure 4
Clonal distribution of BLV positive cells in sheep infected by leukemogenic versus attenuated viruses. Autoradi-
ogram of run-off products (see method). The degree of clonal expansion of infected cells over time was measured by semi-
quantitative quadruplicate IPCR for each animal. (A) Animals #4546 and #4544 were inoculated with the leukemogenic 
molecular clones pBLVTax106+293 and pBLVA60V, respectively. (B) Animals #4543 and #4539 were inoculated with the 
attenuated molecular clones pBLVCRE3X and pBLVCRX3, respectively.Retrovirology 2009, 6:30 http://www.retrovirology.com/content/6/1/30
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10-4, Mann-Whitney test). As described above for proviral
load, the number of abundant infected clones was atypi-
cally extremely high (n = 34) in the sheep 4535 at the
point i+240, thereby increasing the mean value for the
leukemogenic BLV infected group. Except for this time-
point, the degree of clonal expansion was roughly parallel
between animals infected with leukemogenic versus
attenuated BLV infectious molecular clones (Figures 2C,
2D and 4), indicating that attenuated viruses do not alter
the dynamic of the infection over time. Altogether these
results demonstrate that BLV leukemogenicity depends on
the degree of vertical transmission of BLV via infected cell
clonal expansion.
Genetic variability of retroviruses goes hand in hand with
the degree of retroviral replication. In contrast with other
retroviruses, members of HTLV-BLV genus involve two
distinct routes of genetic variability in vivo including RT-
and somatic-associated mechanisms [14,18-20]. The
cycles of reverse transcription govern RT-dependent
genetic variability, whereas extended clonal expansion is
accompanied by somatic rearrangements of integrated
proviruses [19,20]. Having identified high levels of both
BLV replication mechanisms with leukemogenic infec-
tious proviruses, we investigated whether the number of
RT- and somatic-dependent substitutions tended to be
higher in animals infected with leukemogenic BLV molec-
ular clones. To this end, IPCR products of 12 blood sam-
ples, harvested 3 days before, 50 days after seroconversion
and 240 days post infection of 4 sheep (2 from each infec-
tion category) were cloned and sequenced. As previously
described, the alignment of sequenced IPCR products
allowed us to clearly distinguish provirus mutations orig-
inating from somatic- or RT-dependent rearrangements
[14,18-20]. Overall, 834 sequenced molecular clones
were obtained and the alignment of the 3'LTR sequences
with respect to their integration sites allowed the identifi-
cation of 67 distinct infected cellular clones. Their over-
time distributions were 26, 17 and 24 infected cellular
clones at 3 days before, 50 days after seroconversion and
240 days post-inoculation, respectively. The figure 2E
shows the distribution of the mutated cellular clones dur-
ing the course of infection with leukemogenic or attenu-
ated BLV infectious proviruses. For the leukemogenic-BLV
infected sheep, sequence alignments allowed the detec-
tion of 4/16, 3/12 and 2/18 mutated cellular clones with
RT-associated mutation in their proviral sequences at 3
days before, 50 days after seroconversion and 240 days
post-inoculation, respectively. In comparison, at these
respective time-points, attenuated infections displayed 2/
10, 0/5 and 0/6 cellular clones with RT-associated muta-
tion in proviruses. Although different, these values only
reflected the higher amount of clones generated after
infection with leukemogenic viruses: 9 substitutions in 46
cellular clones versus 2 in 21 cellular clones, respectively.
As shown in figure 2E, similar results were obtained when
analyzing the somatic mutation frequencies. Despite an
increased number of cellular clones harboring somatic
mutated proviruses in the leukemogenic BLV infection,
the difference was not significant when the number of
detected clones and the amount of sequenced DNA were
taken into account for leukemogenic versus attenuated
viruses: 4 substitutions in 46 cellular clones (484
sequenced molecular clones, 203 kb of data) versus 1 in
21 cellular clones (350 sequenced molecular clones, 147
kb of data), respectively (Figure 2E). These data indicate
that leukemogenic BLV infection, in comparison to infec-
tion with attenuated BLV infectious molecular clones,
could be characterized by a higher amount of infected
cells with mutated proviruses resulting from RT- and/or
somatic-dependent events. However, the frequencies of
such mutated clones did not change significantly between
the two categories of viruses.
Discussion
This work is the first prospective controlled investigation
of a deltaretrovirus-dependent leukemogenesis that takes
into account the two time-dependent routes of deltaretro-
viruses replication [14,19,20]. The data show that, as early
as 2 weeks after infection and subsequently at any time
during follow-up, leukemogenic viruses displayed signifi-
cantly higher levels of RT and absolute number of RT-
dependent mutation loads, clonal expansion, and clonal
expansion-dependent somatic mutation loads than atten-
uated viruses.
The attenuated viruses correspond to mutated proviral
sequences that retain infectious capacities while display-
ing reduced oncogenic clinical effect after experimental
infection. To date, no BLV-related malignancy has been
described in animals experimentally infected with the
mutants used in the present study. Other attenuated BLV
proviruses, such as those impaired in the accessory pro-
teins R3 and G4 or transmembrane protein TM can induce
lymphoma but at extremely low frequency (≤ 5%) and
after a prolonged period of latency [21]. These molecular
tools rendered it possible to prospectively compare the
replication pattern of leukemogenic versus attenuated
BLV strain in vivo.
Decreased circulating proviral loads have been recently
evidenced at 7 months after experimental infection of
sheep with BLV strains carrying mutations in the genes
that encode R3 and G4 accessory proteins [21]. The
present results confirm and extend these data with other
BLV mutants and reveal that the two routes of BLV repli-
cation (i.e. reverse transcription and clonal expansion)
distinguish the two kinds of viruses, and therefore are
both involved in BLV-dependent leukemogenesis in
sheep. Furthermore, by analyzing BLV replication overRetrovirology 2009, 6:30 http://www.retrovirology.com/content/6/1/30
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time, our study demonstrates that the differences in the
replicative pattern between leukemogenic and attenuated
strains are only quantitative and that both kinds of viruses
trigger parallel temporal fluctuations of viral loads,
infected cell clonality, and proliferation.
Sheep were experimentally infected by intradermal injec-
tion of plasmid DNA, which is not the natural route of
infection for BLV. The virus is transmitted horizontally
through the transfer of infected cells via direct contact,
through milk and blood. The route of infection may influ-
ence the subsequent cellular immune response and
thereby the replication level. This has been documented
with HTLV-1 in experimentally infected adult rats, which
display significantly lower levels of cellular immune
response after gastrointestinal exposure than after intrave-
nous or intraperitoneal inoculation [22]. Therefore, it will
be interesting to test whether the replication and patho-
genicity of leukemogenic or attenuated BLV proviruses
could be influenced by the route of infection.
Deltaretovirus-associated cancers are diseases of long
latency, and the present results suggest that, in addition to
the duration of the infection, a dose effect governs BLV
associated leukemogenesis. Leukemogenic viruses display
an initial burst of intense horizontal RT-dependent replica-
tion that is followed by the extensive clonal expansion of
infected cells. This expansion results in a disease penetrance
rate of ~100% coupled with an extremely short period of
clinical latency in sheep. In contrast, the attenuated virus
replicates poorly by RT and clonal expansion. It either
leaves animals free of tumors or causes disease in a minor-
ity of infected animals only after a prolonged period of
latency. From these data, it is possible to propose that infec-
tion duration and viral dose, which depends on both RT
and clonal expansion, are the two key parameters for tumor
formation. In this model, the lower the replicative viral rate,
the longer the infection course needed for triggering
tumors. Knowing that for sheep infected with wild type BLV
proviruses, premalignant clones are detected as early as 15
days from experimental infection [14]; the present results
suggest that the burst of RT-dependent BLV replication that
characterizes early infection helps to generate premalignant
cells whose subsequent extensive clonal expansion contrib-
utes to transform.
In conclusion these results validate the use of circulating
proviral loads as a clinical prognostic tool for managing
deltaretroviral infections and suggest that targeting both
RT and clonal expansion would be of interest for prevent-
ing associated malignancies.
Methods
Experimental BLV infection of sheep
Fourteen one-year-old sheep were kept under controlled
conditions at the Veterinary and Agrochemical Research
Centre (Machelen, Belgium). The handling of animals
and the experimental procedures were approved by the
ethics committee and were conducted in accordance with
institutional and national guidelines for animal care and
use. Twelve sheep were experimentally infected with BLV
infectious molecular clones as previously described [17].
Briefly, 100 μg of circular plasmid DNA was mixed with
200 μg of Dotap (Roche Diagnostics), and the mixture
was injected intradermally into the back of the sheep. Six
animals were infected with the leukemogenic BLV infec-
tious molecular clones pBLV344, pBLVTax106+293 and
pBLVA60V (2 animals per clone). The pBLV344 was the
wild type infectious molecular clone. The
pBLVTax106+293 was mutated in the Tax phosphoryla-
tion sites[23], and pBLVA60V was mutated at the codon
60 of the GP30 transmembrane gene from alanine into
valine [24]. Two of the 6 animals, sheep #4535 and
#4536, infected with pBLV344 were previously analyzed
for BLV replication and genetic variability [18]. Six addi-
tional sheep were infected with cloned viruses
pBLVCRE3X, pBLVCRX3 and pBLVIG4 [15] (2 animals
per clone). The pBLVCRE3X was mutated for CRE imper-
fect sequences to TGACGTCA [25] whereas pBLVCRX3
was deleted in R3 [8] and pBLVIG4 harbored a stop codon
in the G4 open reading frame[16]. Two of the 6 animals
infected with those attenuated infectious viruses, sheep
#4537 and #4538, infected with pBLVIG4 were previously
analyzed for BLV replication and genetic variability [18].
Two additional sheep, #4533 and 4534, inoculated with a
BLV-negative Dotap solution served as uninfected con-
trols. Twice a week, the total leukocyte counts were deter-
mined by using a Coulter counter ZN, and the number of
lymphocytes was estimated after examination under the
microscope after staining with May-Grunwald Giemsa. In
parallel, the sera from each sheep were analyzed for BLV
seropositivity as described [26].
Measurement of circulating BLV proviral load
The circulating amounts of BLV proviral sequences were
measured by LightCycler quantitative PCR as described
[14]. Briefly, the reaction mixture included polymerase
(LightCycler Kit Fast Start DNA Master Hybridization
Probes; Roche), 2 mM MgCl 2, 500 nM primer BLVQF,
500 nM primer BLVQR, both targeting the Px region, and
100 nM donor probe 3' end labeled with fluorescein and
200 nM acceptor probe 5' end labeled with LC Red640.
Standardization of the amount of DNA subjected to quan-
tification was performed with the sheep beta-globin gene
as an internal standard [27].
Detection and quantification of the clonal distribution of 
circulating BLV positive cells in vivo
BLV integration was analyzed by Inverse Polymerase
Chain Reaction (IPCR) as described [14]. Briefly, two
micrograms of DNA were digested by 20 U NlaIII and 20
units of MfeI in 1× NlaIII-MfeI buffer for 3 hours at 37°C.Retrovirology 2009, 6:30 http://www.retrovirology.com/content/6/1/30
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MfeI digestion was performed in order to avoid the ampli-
fication of a 536 bp segment of the 5' LTR complementary
to the set of 3' IPCR primers. One microgram of digested
DNA was circularized for 16 hours at 16°C with 20 U of
T4 DNA ligase. Samples were analyzed in quadruplicate,
as previously described for BLV and HTLV-1 [14,28]: 4 ×
500 ng of circularized DNA were amplified for 39 cycles
using 200 μM of the primer pair BLV3'S and BLV3'AS.
Amplifications were performed using 3.5 units of the Pfu
DNA polymerase with thermal cycling parameters as fol-
lows: 95°C 10 minute, 35 × (95°C 1 min, 60°C 1 minute,
72°C 3 minutes), and a final elongation step of 10 min-
utes at 72°C. The length polymorphism analysis of 3' BLV
flanking sequences was performed by making a run-off.
This method consists in the linear PCR amplification of
the provirus 3' extremities together with their flanking
sequences. Two microliters of amplified IPCR products
were submitted to 10 cycles of linear PCR with 2 μM of 5'-
32P-radiolabeled primer BLV3'RO. Run-off products were
analyzed on a 6% sequencing gel. As previously described
[14], the stochastic nature of BLV IPCR was found to
appear at BLV integration site frequencies ranging
between 25 and 2400 copies of the BLV provirus per mcg
of blood DNA. At copy numbers ranging from 1200 to
2400, 62.5 to 1200, and 25 to 62.5, detection was 3/4, 2/
4, and 1/4, respectively. Accordingly, DNA samples from
BLV infected animals were analyzed in quadruplicate (4 ×
0.5 mcg).
Assessment of BLV genetic variability in vivo
The cloning and sequencing of 3'LTR-integration site PCR
fragments were performed as previously described [14].
Briefly, purified IPCR products were ligated with SmaI-
digested and M13mp18 replicative form DNA. After trans-
formation of Escherichia coli XL1, recombinant M13
plaques were screened by hybridization with the BLV3'RO
oligonucleotides. Single-stranded templates were
sequenced using fluorescent dideoxynucleotides. The
sequenced products were resolved on an Applied Biosys-
tems 377A DNA sequencer with 377A software. Sequence
alignments were performed with Sequence Navigator
Software.
Statistical analysis
SPSS statistical software version 11 was used for analyses.
The correlation of data was assessed by Spearman's Rho
nonparametric method. P < 0.05 was considered signifi-
cant in all analyses.
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